Bis(4-nitrophenyl) (oxybis(ethane-2,1-diyl)) bis(carbonate) | 113629-16-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Bis(4-nitrophenyl) (oxybis(ethane-2,1-diyl)) bis(carbonate)
• 英文别名: 2-[2-(4-nitrophenoxy)carbonyloxyethoxy]ethyl (4-nitrophenyl) carbonate
• CAS: 113629-16-6
• 化学式: C₁₈H₁₆N₂O₁₁
• 分子量: 436.332
• InChiKey: ARLIKDUPRNWWEX-UHFFFAOYSA-N

物化性质

• 沸点：
  619.4±55.0 °C(Predicted)
• 密度：
  1.447±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  172
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  Bis(4-nitrophenyl) (oxybis(ethane-2,1-diyl)) bis(carbonate) 在 4-二甲氨基吡啶 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 29.0h， 生成 2-[2-[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methylcarbamoyloxy]ethoxy]ethyl N-[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl]carbamate
  参考文献：
  名称：

  The First Direct Evaluation of the Two-Active Site Mechanism for Chitin Synthase

  摘要：

  Chitin synthase polymerizes UDP-GlcNAc to form chitin (poly-beta(1,4)-G1cNAc) and is essential for fungal cell wall biosynthesis. The alternating orientation of the GlcNAc residues within the chitin chain has led to the proposal that chitin synthase possesses two active sites. We report the results of the first direct test of this possibility. Two simple uridine-derived dimeric inhibitors are shown to exhibit 10-fold greater inhibition than a monomeric control, consistent with the presence of two active sites. This observation has important implications for the development of antifungal agents, as well as the understanding of polymerizing glycosyltransferases.

  DOI：

  10.1021/jo035100c
• 作为产物：
  描述：

  对硝基苯基氯甲酸酯 、 二乙二醇 在 吡啶 作用下， 反应 40.0h， 以46%的产率得到Bis(4-nitrophenyl) (oxybis(ethane-2,1-diyl)) bis(carbonate)
  参考文献：
  名称：

  The First Direct Evaluation of the Two-Active Site Mechanism for Chitin Synthase

  摘要：

  Chitin synthase polymerizes UDP-GlcNAc to form chitin (poly-beta(1,4)-G1cNAc) and is essential for fungal cell wall biosynthesis. The alternating orientation of the GlcNAc residues within the chitin chain has led to the proposal that chitin synthase possesses two active sites. We report the results of the first direct test of this possibility. Two simple uridine-derived dimeric inhibitors are shown to exhibit 10-fold greater inhibition than a monomeric control, consistent with the presence of two active sites. This observation has important implications for the development of antifungal agents, as well as the understanding of polymerizing glycosyltransferases.

  DOI：

  10.1021/jo035100c

文献信息

• [EN] VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES<br/>[FR] ANTICORPS FONCTIONNALISÉS BILATÉRALEMENT PAR CYCLOADDITION
  申请人：SYNAFFIX BV

  公开号：WO2021144314A1

  公开（公告）日：2021-07-22

  The present invention provides antibody-payload conjugates having a payload-to-antibody ratio of 1. The antibody-payload conjugate is according to structure (1): formula (1), wherein: - a, b, c and d are each independently 0 or 1; - e is an integer in the range of 0 - 10; - L1, L2 and L3 are linkers; - D is a payload; - BM is a branching moiety; - Su is a monosaccharide; - G is a monosaccharide moiety; - GlcNAc is an N-acetylglucosamine moiety; - Fuc is a fucose moiety; - Z are connecting groups. The invention further provides a method for preparing the antibody-payload conjugate according to the invention, an intermediate compound in that preparation method, and medical uses of the antibody-payload conjugate according to the invention.

  本发明提供了一种抗体-有效载荷偶联物，其有效载荷与抗体的比例为1。所述抗体-有效载荷偶联物如结构(1)所示：公式(1)，其中：- a、b、c和d每个独立地为0或1；- e是0至10之间的整数；- L1、L2和L3是连接臂；- D是有效载荷；- BM是分支基团；- Su是单糖；- G是单糖基团；- GlcNAc是N-乙酰葡萄糖胺基团；- Fuc是岩藻糖基团；- Z是连接基团。本发明还提供了根据本发明制备抗体-有效载荷偶联物的方法、该制备方法中的中间化合物，以及根据本发明的抗体-有效载荷偶联物的医疗用途。
• Main Chain Acid-Degradable Polymers for the Delivery of Bioactive Materials
  申请人：Frechet Jean M.J.

  公开号：US20090220615A1

  公开（公告）日：2009-09-03

  Novel main chain acid degradable polymer backbones and drug delivery systems comprised of materials capable of delivering bioactive materials to cells for use as vaccines or other therapeutic agents are described. The polymers are synthesized using monomers that contain acid-degradable linkages cleavable under mild acidic conditions. The main chain of the resulting polymers readily degrade into many small molecules at low pH, but remain relatively stable and intact at physiological pH. The new materials have the common characteristic of being able to degrade by acid hydrolysis under conditions commonly found within the endosomal or lysosomal compartments of cells thereby releasing their payload within the cell. The materials can also be used for the delivery of therapeutics to the acidic regions of tumors and other sites of inflammation.

  本文介绍了一种新型主链酸可降解聚合物骨架和药物传递系统，由能够向细胞输送生物活性物质以用作疫苗或其他治疗剂的材料组成。这些聚合物是使用含有酸可降解键的单体合成的，这些键在温和酸性条件下可被裂解。由此产生的聚合物主链能够在低pH值下迅速降解为许多小分子，但在生理pH下仍相对稳定完整。这些新材料具有共同的特点，即能够在细胞内部体液或溶酶体等常见酸性条件下通过酸水解逐渐降解，从而释放其有效载荷。这些材料还可用于将治疗剂输送到肿瘤和其他炎症部位的酸性区域。
• [EN] MULTIFUNCTIONAL ANTIBODIES<br/>[FR] ANTICORPS MULTIFONCTIONNELS
  申请人：SYNAFFIX BV

  公开号：WO2022167689A9

  公开（公告）日：2022-11-10

  The present invention concerns multifunctional antibody construct containing at least one antibody Ab and two distinct payloads D1and D2of structure (1) or (2). Wherein L1, L2, L3, L4and L5are linkers; x1 and x2 are each individually an integer in the range of 1 – 8, wherein x1 + x2 = 2 - 10; BM is a branching moiety; m and n are each independently 0 or 1; x3 is an integer in the range of 1 - 4; and D1and D2are two distinct payloads selected from the group consisting of polypeptides, small molecules, cytotoxins and oligonucleotides, wherein at least one of D1and D2is a polypeptide. The multifunctional antibody construct according to invention are suitable for use in medicine, such as for use in the treatment of cancer, a viral infection, a bacterial infection, a neurological disease, an autoimmune disease, an eye disease, hypercholesterolemia and amyloidosis.

  本发明涉及一种多功能抗体构造体，该构造体包含至少一种抗体Ab和两种不同的结构（1）或（2）的有效载荷D1和D2。其中，L1、L2、L3、L4和L5是连接物；x1和x2分别是1-8范围内的整数，其中x1 + x2 = 2-10；BM是分支基团；m和n各自独立地为0或1；x3是1-4范围内的整数；D1和D2是从包括多肽、小分子、细胞毒素和寡核苷酸在内的一组不同有效载荷中选择的两种不同有效载荷，其中至少一个是多肽。本发明的多功能抗体构造体适用于医学，例如用于治疗癌症、病毒感染、细菌感染、神经系统疾病、自身免疫性疾病、眼部疾病、高胆固醇血症和淀粉样变性疾病。
• Combinatorial Screening of Biscarbamate Ionizable Lipids Identifies a Low Reactogenicity Lipid for Lipid Nanoparticle mRNA Delivery
  作者：Emily De Lombaerde、Yong Chen、Tingting Ye、Julie Deckers、Giulia Mencarelli、Kim De Swarte、Heleen Lauwers、Ruben De Coen、Sabah Kasmi、Sanne Bevers、Anna Kuchmiy、Bram Bogaert、Lies Baekens、Zifu Zhong、Alexander Lamoot、Niek N. Sanders、Bart N. Lambrecht、Antonio P. Baptista、Stefaan De Koker、Bruno G. De Geest

  DOI：10.1002/adfm.202310623

  日期：——

  Messenger RNA (mRNA) has emerged as a promising therapeutic modality for various diseases. However, efficient delivery of mRNA into target cells remains a significant challenge. In this study, the combinatorial synthesis and characterization of a novel series of ionizable biscarbamate lipids (IBLs) for mRNA lipid nanoparticle (LNP) delivery are reported. A simplified and scalable method is developed

  信使 RNA (mRNA) 已成为多种疾病的一种有前途的治疗方式。然而，将 mRNA 有效递送到靶细胞中仍然是一个重大挑战。在这项研究中，报告了用于 mRNA 脂质纳米颗粒 (LNP) 递送的一系列新型可电离双氨基甲酸酯脂质 (IBL) 的组合合成和表征。开发了一种简化且可扩展的方法，产生适合将 mRNA 配制为稳定 LNP 的 IBL。使用 eGFP 作为报告蛋白，合成了两代 IBL，并在体外评估了它们的 mRNA 转染能力，从而确定了 S-Ac7-DOG 作为先导 IBL。肌肉注射疫苗后，S-Ac7-DOG LNP 会引发针对 mRNA 编码的病毒癌蛋白和肿瘤新抗原的强烈抗原特异性 CD8+ T 细胞反应。与用作基准的 MC3 LNP 相比，S-Ac7-DOG LNP 表现出低反应原性、强大的 mRNA 转染和独特的生物分布，在引流淋巴结和脾脏中积累更高。这些发现凸显了 IBL 作为一
• [EN] CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS<br/>[FR] CONJUGUÉS D'ANTICORPS ET D'AGENTS DE MISE EN CONTACT DE CELLULES IMMUNITAIRES
  申请人：SYNAFFIX BV

  公开号：WO2021144315A9

  公开（公告）日：2022-11-17